SCHEMBL2999753

SCHEMBL2999753

COc1ccc(OC)c(Cc2csc(N3CCC(S(=O)(=O)c4cccc(C(F)(F)F)c4)CC3)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
LMNA P02545 3/20 0.45
TSHR P16473 3/20 0.45
GAA P10253 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
ADORA2A P29274 2/20 0.45
ADORA2B P29275 2/20 0.45
ADORA1 P30542 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
ALOX15 P16050 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CTSS P25774 1/20 0.41
KCNQ1 P51787 1/20 0.40
CACNA1B Q00975 2/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022153 0.94 MAPT (0.43) MAPTLMNATSHRGAANPSR1
SCHEMBL3015867 0.91 ADORA2A (0.45) MAPTLMNATSHRGAANPSR1
SCHEMBL3012854 0.90 THRB (0.41) MAPTLMNATSHRTDP1KCNQ1
SCHEMBL3015619 0.89 MAPT (0.47) MAPTLMNATSHRGAANPSR1
SCHEMBL3019030 0.88 KDM1A (0.39) MAPTLMNATSHRGAANPSR1
SCHEMBL3016957 0.88 TP53 (0.37) MAPTLMNATSHRALDH1A1TDP1
SCHEMBL3021601 0.88 CTSS (0.43) MAPTLMNATSHRGAANPSR1
SCHEMBL3002769 0.87 L3MBTL1 (0.49) MAPTLMNATSHRGAANPSR1
SCHEMBL3021700 0.87 ADORA2A (0.46) MAPTLMNATSHRGAANPSR1
SCHEMBL3008333 0.87 CTSS (0.44) MAPTLMNATSHRGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.